NCT01120821

Treatment of Polycythemia Vera With Gleevec

A Phase II Trial of the Treatment of Polycythemia Vera With Gleevec

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Weill Medical College of Cornell University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to evaluate the safety and effectiveness of patients with Polycythemia Vera treated with Gleevec.

Detailed description

Phlebotomy is a standard temporizing treatment for Polycythemia Vera. Performing repeated phlebotomies may lead to iron deficiency and can contribute to a rising platelet count. This may create additional problems, such as clots particularly in patients older than 50. There is reason to believe that the use of Gleevec may cause a decrease in the activity of the marrow so that patients may not require as many or any phlebotomies. Thus, spleen function may possibly improve by decreasing in size and patients' platelet counts may also improve.

Conditions

• Polycythemia Vera

Interventions

Type	Name	Description
DRUG	Gleevec	400 mg once daily for 12 months

Timeline

• Start date: 2002-08-01
• Primary completion: 2007-01-01
• Completion: 2007-06-01
• First posted: 2010-05-11
• Last updated: 2010-05-17

Locations

1 site across 1 country: United States